• Health Catalyst Invests In healthfinch

    To kick off the third quarter, Health Catalyst has announced its second acquisition of 2020. On July 9, the company announced it acquired healthfinch, Inc. for roughly $40 million. healthfinch provides a workflow integration engine delivering insights and analytics into EMR workflows to automate physicians’ ability to close patient care gaps in... Read More »
  • Second Quarter Healthcare M&A Activity Drops

    The decline in second quarter healthcare M&A probably won’t surprise many of our readers. The second quarter was the first full quarter of healthcare M&A in the shadow of the COVID-19 pandemic, and deal making took a hit as a result, as shown in results from our DSO database. Compared with Q1:20, Q2:20 dropped 20%, with 322 transactions... Read More »
  • Sanofi Inks New Licensing Deal

    Just weeks following its agreement with Translate Bio (NASDAQ: TBIO) for COVID-19 vaccine development, Sanofi (NYSE: SNY) has a new agreement with Kymera Therapeutics Inc. Sanofi and Kymera are signing a multi-program collaboration to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with... Read More »
  • Summit BHC Expands Into West Virginia

    Private equity-backed Summit BHC has announced a new acquisition in West Virginia. The behavioral health treatment company added Highland Hospital to its network for an undisclosed sum. Meridian Behavioral Health Systems, LLC is selling Highland Hospital, an inpatient psychiatric facility (131 beds) with 24 beds dedicated to psychiatric... Read More »
  • Health Care M&A Deals, July 10, 2020

    The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week based on... Read More »

Teva Unloads 15 Generics on Impax

To fulfill a condition of its $40.1 billion acquisition of Allergan’s (NYSE: AGN) U.S. generics business, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) agreed to sell a broad portfolio of generic products across solid oral, inhalable, injectable and topical dosage forms to Impax Laboratories Inc. (NASDAQ: IPXL). The $586 million price includes the return to Impax of its rights to its pending Abbreviated New Drug Application (ANDA) for the generic equivalent to Concerta®. Impax is using existing cash and $400 million in new fully committed term loans, provided by RBC Capital Markets. Upon closing, Impax expects to add a portfolio of 15 currently marketed generic products; one... Read More »

New MainStream Adds Constellation Behavioral

Constellation Behavioral Health, LLC became the fourth healthcare services company in New MainStream Capital’s portfolio on May 19. Constellation joins Anne Arundel Dermatology, MCCI Medical Group and Suncrest Home Health. Based in Mill Valley, California, Constellation offers specialized inpatient and outpatient treatment programs for addiction, mental health and co-occurring behavioral health disorders. Founder and CEO William Morrison will retain a minority stake. Constellation operates two facilities in California: Alta Mira and Bridges to Recovery. Alta Mira is a 30-bed facility in Sausalito, California with 30,000 square feet. Bridges to Recovery is a 12-bed facility in Los... Read More »